BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to AustraliaHOUSTON, TX / ACCESS Newswire / September 9, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on developing potentially curative therapies for advanced cancers - today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet's manufacturing subsidiary is located.
